Submitted by Anonymous (not verified) on 10 August 2023 - 9:20
Human medicines European public assessment report (EPAR): Ilumetri, tildrakizumab, Psoriasis, Date of authorisation: 17/09/2018, Revision: 10, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Ilumetri, tildrakizumab, Psoriasis, Date of authorisation: 17/09/2018, Revision: 10, Status: Authorised